Alacrita Life Science Consulting Alacrita Life Science Consulting
  • Our Services
    • Product Development
      • Research & IP Evaluation
      • Preclinical Strategy & Execution
      • Clinical Development
      • Regulatory Affairs
      • CMC Consulting
      • Interim Chief Medical Officer
    • Strategy & Commercialization
      • Opportunity Mapping
      • Business Plans & Fundraising Support
      • New Product Planning
      • Launch Planning
    • Business Development
      • Due Diligence
      • Valuations
      • In-Licensing & Asset Scouting
      • Out-Licensing, Partnering & Deal-making
    • Expert Witness Services
    • By Client Type
      • Biotech
      • Virtual & Semi-Virtual Biotechs
      • Pharmaceutical Companies
      • Investors
      • Tech Transfer Offices
      • Animal Health Companies
    • By Product Modality
      • Antibodies, ADCs
      • Cell Therapies
      • Drug Discovery Platforms
      • Gene Therapies
      • Microbiome Drugs
      • Peptides & Proteins
      • Radiopharmaceuticls
      • Small Molecules
      • Other Product Modalities
    • By Disease Area
      • CNS
      • Digestive & GI
      • Endocrine & Metabolic
      • Fibrosis
      • Hematology
      • Immunology
      • Oncology
      • Respiratory
      • Other Disease Areas
  • Core Team
    • Alastair Southwell
    • Anthony Walker
    • Saadia Anastasiou
    • Michael Lombardo
    • Lucas Rodriguez
    • Mark Philip
    • Nigel Burns
    • Gary Mansfield
    • Christine McCarthy
    • Stuart Hendry
    • Simon Turner
    • Pierre Dodion
  • Consulting Network
  • Resources
    • Case Studies
    • Blog
    • News
    • Whitepapers
  • Careers
  • Contact

Whitepapers

  • news and resources
  • Whitepapers

China: Opportunities for biotech firms

24th March 2011
China is serious about medicine. Universal access to basic healthcare, an improving IP environment, Chinese companies desire for innovation and substantial funding opportunities are opening up...
Learn More

Re-Profiling: a Hidden Threat to Originators?

25th February 2011
As James Black is famously quoted as saying, "the most fruitful basis for the discovery of a new drug is to start with an old drug". This has stimulated a heightened search for new indications for...
Learn More

Mitigating Out-sourcing Risk

29th December 2010
Many firms that outsource major projects can end up managing relationships at arms-length. For complex, business-critical projects, this is a high risk strategy as it may fail to give sufficient...
Learn More

Deal Watch: a Review of Notable Deals

29th October 2010
Sharon Finch, Alacrita Advisory Board Member, has published a review of notable deals.
Learn More
Previous
1 2 3 4

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

  • Strategy and Commercialization Learn more
  • Product Development Learn more
  • Business Development Learn more

© 2009-25 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

  • Privacy Notice

Alacrita Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.

Alacrita Life Science Consulting Alacrita Life Science Consulting